Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Director | June 10, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2036-06-10 | Direct | 160,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 20,000 · Balance 160,000 F1: On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2: The option is 100% vested on date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
F2: The option is 100% vested on date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 10, 2026 21:27 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 20,000 | $8.70 Strike: $8.70 | $174,000.00 |
DisclosureSEC source: 0001791004-26-000002 · form4-06102026_090632.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Shares · 20,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 20,000 | $7.88 Strike: $7.88 | $157,600.00 |
DisclosureSEC source: 0001415889-25-015589 · form4-06042025_040611.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 20,000 shares Expires 2035-06-03 F1 · security: On June 3, 2025, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:01 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 20,000 | $5.58 Strike: $5.58 | $111,600.00 |
DisclosureSEC source: 0001415889-24-021640 · form4-08192024_110834.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Shares · 20,000 shares Expires 2034-08-15 F1 · security: On August 15, 2024, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 15:47 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-23-009705 · form4-06132023_030634.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 20,000 shares Expires 2033-06-12 F1 · security: On June 12, 2023, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 13:22 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001104659-22-071686 · tm2218610-2_4seq1.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2032-06-14 F1 · security: On June 14, 2022, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 19:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001104659-21-087513 · tm2121155-2_4seq1.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-06-29 F1 · security: On June 29, 2021, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 19:15 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001104659-20-095444 · tm2027709d2_4.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2030-08-13 F1 · security: On August 13, 2020, Jodi Cook was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 16:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001104659-19-063937 · tm1922795d2_4.xml · derivative · entry 1 Cook Jodi A · CIK 0001791004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-11-13 F1 · security: On November 13, 2019, Jodi Cook was granted an incentive stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. 100% of the shares under this option were fully vested on the date of grant Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.